Evidence map›Paper›PMID 41788173›Full record

ArticleJournal of traditional and complementary medicine2026

Zhoushi Qiling decoction inhibits neuregulin 1 secreted from cancer-associated fibroblasts to ameliorate enzalutamide resistance in prostate cancer.

Chunyu Wang, Hongwen Cao, Peng Sun, Lei Chen, Yigeng Feng, Renjie Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional and complementary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chunyu WangSurgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai, 200032, China.
Hongwen CaoSurgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai, 200032, China.
Peng SunSurgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai, 200032, China.
Lei ChenSurgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai, 200032, China.
Yigeng FengSurgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai, 200032, China.
Renjie GaoSurgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai, 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: Zhoushi Qiling decoction (ZQD) has emerged as a promising therapeutic agent for improving outcomes in prostate cancer treatment. This study aimed to evaluate the efficacy of ZQD on enzalutamide-resistant prostate cancer cells and to elucidates the underlying mechanisms. Experimental procedure: A co-culture model consisting of cancer-associated fibroblasts (CAFs) and enzalutamide-resistant prostate cancer cells was established and treated with ZQD-containing serum. Cell proliferation and viability were assessed using colony formation and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. The anti-tumor effects of ZQD were further evaluated in an Results: ZQD-containing serum inhibited the expression of neuregulin 1 (NRG1) in CAFs. It also reversed CAF-induced enzalutamide resistance and reduced CAF-stimulated proliferation of enzalutamide-resistant prostate cancer cells. In addition, ZQD suppressed NRG1 secretion and phosphorylation of human epidermal growth factor receptor 3 (HER3) in these cells. The serum also demonstrated inhibitory effects on matrix metalloproteinases (MMP-1 and MMP-9) in enzalutamide-resistant prostate cancer cells. Conclusion: ZQD effectively inhibits NRG1 secretion from CAFs and mitigates enzalutamide resistance in prostate cancer. These findings provide a scientific basis for the potential clinical application of ZQD in overcoming enzalutamide resistance in prostate cancer treatment.

Indexed as

Cancer-associated fibroblastsEnzalutamide resistanceNRG1Prostate cancerZhoushi Qiling decoction

Identifiers

PMID41788173
PMCPMC12957806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.